Skip to main content
Top
Published in: BMC Neurology 1/2019

Open Access 01-12-2019 | Stroke | Research article

A systematic review and meta-analysis of interventions to increase stroke thrombolysis

Authors: Mollie McDermott, Lesli E. Skolarus, James F. Burke

Published in: BMC Neurology | Issue 1/2019

Login to get access

Abstract

Background

Although the efficacy of tissue plasminogen activator (tPA) for acute ischemic stroke is well established, rates of tPA use remain low. For clinicians, advocates, and policy-makers seeking to increase tPA treatment rates, it is important to understand what interventions exist and their relative effectiveness.

Methods

We searched PubMed and EMBASE to identify all studies published between 1995 and January 8, 2015 documenting interventions to increase the use of tPA with broadly inclusive criteria. The principal summary measure was the percentage change in rate of tPA administration. Random effects meta-analytic models were built to summarize the effect of intervention compared to control overall and for intervention characteristics.

Results

The search yielded 1457 results of which 25 met eligibility criteria. We identified 14 pre-post studies, ten randomized controlled trials, and one quasi-experiment. Included studies targeted their interventions at emergency medical services (EMS) (n = 14), telemedicine (n = 6), and public education (n = 6). In a random effects model, tPA administration was significantly higher in the intervention arm across all studies limiting enrollment to ischemic stroke patients (n = 16) with a risk ratio (RR) of 1.80 (95% confidence interval [CI], 1.45–2.22). A trend towards increased tPA administration was observed for all intervention approaches: risk ratio of 1.73 (95% CI, 1.44–2.09) for EMS, 1.58 (95% CI, 0.72–3.47) for telemedicine, and 1.89 (95% CI, 0.77–4.65) for public education, the latter not restricted to ischemic stroke patients.

Conclusions

Interventions to increase tPA use appear to have considerable effectiveness. Our findings support the use of such interventions to improve stroke outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference The National Institute of Neurological Disorders and Stroke rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.CrossRef The National Institute of Neurological Disorders and Stroke rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.CrossRef
2.
go back to reference Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947.CrossRef Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947.CrossRef
3.
go back to reference Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008;39:924–8.CrossRef Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008;39:924–8.CrossRef
4.
go back to reference Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med. 2010;5:406–9.CrossRef Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med. 2010;5:406–9.CrossRef
5.
go back to reference Lees KR, Ford GA, Muir KW, et al. Thrombolytic therapy for acute stroke in the United Kingdom: experience from the safe implementation of thrombolysis in stroke (SITS) register. QJM. 2008;101:863–9.CrossRef Lees KR, Ford GA, Muir KW, et al. Thrombolytic therapy for acute stroke in the United Kingdom: experience from the safe implementation of thrombolysis in stroke (SITS) register. QJM. 2008;101:863–9.CrossRef
6.
go back to reference Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke. 2005;36:2500–3.CrossRef Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke. 2005;36:2500–3.CrossRef
7.
go back to reference Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2013;61:46–55.CrossRef Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2013;61:46–55.CrossRef
8.
go back to reference Boudreau DM, Guzauskas GF, Chen E, et al. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke. 2014;45:3032–9.CrossRef Boudreau DM, Guzauskas GF, Chen E, et al. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke. 2014;45:3032–9.CrossRef
9.
go back to reference Penaloza-Ramos MC, Sheppard JP, Jowett S, et al. Cost-effectiveness of optimizing acute stroke care services for thrombolysis. Stroke. 2014;45:553–62.CrossRef Penaloza-Ramos MC, Sheppard JP, Jowett S, et al. Cost-effectiveness of optimizing acute stroke care services for thrombolysis. Stroke. 2014;45:553–62.CrossRef
10.
go back to reference Skolarus LE, Meurer WJ, Shanmugasundaram K, Adelman EE, Scott PA, Burke JF. Marked regional variation in acute stroke treatment among Medicare beneficiaries. Stroke. 2015;46:1890–6.CrossRef Skolarus LE, Meurer WJ, Shanmugasundaram K, Adelman EE, Scott PA, Burke JF. Marked regional variation in acute stroke treatment among Medicare beneficiaries. Stroke. 2015;46:1890–6.CrossRef
11.
go back to reference Adeoye O, Albright KC, Carr BG, et al. Geographic access to acute stroke care in the United States. Stroke. 2014;45:3019–24.CrossRef Adeoye O, Albright KC, Carr BG, et al. Geographic access to acute stroke care in the United States. Stroke. 2014;45:3019–24.CrossRef
12.
go back to reference Williams LS, Bruno A, Rouch D, Marriott DJ. Stroke patients' knowledge of stroke: influence on time to presentation. Stroke. 1997;28:912–5.CrossRef Williams LS, Bruno A, Rouch D, Marriott DJ. Stroke patients' knowledge of stroke: influence on time to presentation. Stroke. 1997;28:912–5.CrossRef
13.
go back to reference Kothari R, Sauerbeck L, Jauch E, et al. Patients' awareness of stroke signs, symptoms, and risk factors. Stroke. 1997;28:1871–5.CrossRef Kothari R, Sauerbeck L, Jauch E, et al. Patients' awareness of stroke signs, symptoms, and risk factors. Stroke. 1997;28:1871–5.CrossRef
14.
go back to reference Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from tPA therapy?: an analysis of patient eligibility. Neurology. 2001;56:1015–20.CrossRef Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from tPA therapy?: an analysis of patient eligibility. Neurology. 2001;56:1015–20.CrossRef
15.
go back to reference Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004;61:346–50.CrossRef Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004;61:346–50.CrossRef
16.
go back to reference Morris DL, Rosamond W, Madden K, Schultz C, Hamilton S. Prehospital and emergency department delays after acute stroke: the Genentech stroke presentation survey. Stroke. 2000;31:2585–90.CrossRef Morris DL, Rosamond W, Madden K, Schultz C, Hamilton S. Prehospital and emergency department delays after acute stroke: the Genentech stroke presentation survey. Stroke. 2000;31:2585–90.CrossRef
17.
go back to reference Tai YJ, Yan B. Minimising time to treatment: targeted strategies to minimise time to thrombolysis for acute ischaemic stroke. Intern Med J. 2013;43:1176–82.CrossRef Tai YJ, Yan B. Minimising time to treatment: targeted strategies to minimise time to thrombolysis for acute ischaemic stroke. Intern Med J. 2013;43:1176–82.CrossRef
18.
go back to reference Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34.CrossRef Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34.CrossRef
19.
go back to reference Dreyer NA, Velentgas P, Westrich K, Dubois R. The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution. J Manag Care Spec Pharm. 2014;20:301–8.PubMed Dreyer NA, Velentgas P, Westrich K, Dubois R. The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution. J Manag Care Spec Pharm. 2014;20:301–8.PubMed
21.
go back to reference Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA. 2014;311:1632–40.CrossRef Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA. 2014;311:1632–40.CrossRef
22.
go back to reference Dirks M, Niessen LW, van Wijngaarden JD, et al. Promoting thrombolysis in acute ischemic stroke. Stroke. 2011;42:1325–30.CrossRef Dirks M, Niessen LW, van Wijngaarden JD, et al. Promoting thrombolysis in acute ischemic stroke. Stroke. 2011;42:1325–30.CrossRef
23.
go back to reference Scott PA, Meurer WJ, Frederiksen SM, et al. A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trial. Lancet Neurol. 2013;12:139–48.CrossRef Scott PA, Meurer WJ, Frederiksen SM, et al. A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trial. Lancet Neurol. 2013;12:139–48.CrossRef
24.
go back to reference Berglund A, Svensson L, Sjostrand C, et al. Higher prehospital priority level of stroke improves thrombolysis frequency and time to stroke unit: the hyper acute stroke alarm (HASTA) study. Stroke. 2012;43:2666–70.CrossRef Berglund A, Svensson L, Sjostrand C, et al. Higher prehospital priority level of stroke improves thrombolysis frequency and time to stroke unit: the hyper acute stroke alarm (HASTA) study. Stroke. 2012;43:2666–70.CrossRef
25.
go back to reference Quain DA, Parsons MW, Loudfoot AR, et al. Improving access to acute stroke therapies: a controlled trial of organised pre-hospital and emergency care. Med J Aust. 2008;189:429–33.PubMed Quain DA, Parsons MW, Loudfoot AR, et al. Improving access to acute stroke therapies: a controlled trial of organised pre-hospital and emergency care. Med J Aust. 2008;189:429–33.PubMed
26.
go back to reference Muller-Barna P, Hubert GJ, Boy S, et al. Telestroke units serving as a model of care in rural areas: 10-year experience of the telemedical project for integrative stroke care. Stroke. 2014;45:2739–44.CrossRef Muller-Barna P, Hubert GJ, Boy S, et al. Telestroke units serving as a model of care in rural areas: 10-year experience of the telemedical project for integrative stroke care. Stroke. 2014;45:2739–44.CrossRef
27.
go back to reference Morgenstern LB, Staub L, Chan W, et al. Improving delivery of acute stroke therapy: the TLL Temple Foundation stroke project. Stroke. 2002;33:160–6.CrossRef Morgenstern LB, Staub L, Chan W, et al. Improving delivery of acute stroke therapy: the TLL Temple Foundation stroke project. Stroke. 2002;33:160–6.CrossRef
28.
go back to reference Yamal JM, Rajan SS, Parker SA, et al. Benefits of stroke treatment delivered using a mobile stroke unit trial. Int J Stroke. 2018;13:321–7.CrossRef Yamal JM, Rajan SS, Parker SA, et al. Benefits of stroke treatment delivered using a mobile stroke unit trial. Int J Stroke. 2018;13:321–7.CrossRef
29.
go back to reference Kunz A, Ebinger M, Geisler F, et al. Functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care: an observational registry study. Lancet Neurol. 2016;15:1035–43.CrossRef Kunz A, Ebinger M, Geisler F, et al. Functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care: an observational registry study. Lancet Neurol. 2016;15:1035–43.CrossRef
30.
go back to reference Audebert H, Fassbender K, Hussain MS, et al. The pre-hospital stroke treatment organization. Int J Stroke. 2017;12:932–40.CrossRef Audebert H, Fassbender K, Hussain MS, et al. The pre-hospital stroke treatment organization. Int J Stroke. 2017;12:932–40.CrossRef
31.
go back to reference Walter S, Kostopoulos P, Haass A, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol. 2012;11:397–404.CrossRef Walter S, Kostopoulos P, Haass A, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol. 2012;11:397–404.CrossRef
32.
go back to reference Ebinger M, Winter B, Wendt M, et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA. 2014;311:1622–31.CrossRef Ebinger M, Winter B, Wendt M, et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA. 2014;311:1622–31.CrossRef
Metadata
Title
A systematic review and meta-analysis of interventions to increase stroke thrombolysis
Authors
Mollie McDermott
Lesli E. Skolarus
James F. Burke
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2019
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-019-1298-2

Other articles of this Issue 1/2019

BMC Neurology 1/2019 Go to the issue